Erik Harris - 06 May 2021 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
EVP & Chief Commercial Officer
Signature
/s/ Karah Parschauer, attorney-in-fact
Issuer symbol
RARE
Transactions as of
06 May 2021
Net transactions value
-$79,572
Form type
4
Filing time
10 May 2021, 18:10:37 UTC
Next filing
23 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Sale $34,900 -307 -1.1% $113.68 27,110 06 May 2021 Direct F1
transaction RARE Common Stock Sale $44,672 -393 -1.4% $113.67 26,717 07 May 2021 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
F2 The sales reported on the transaction date of May 7, 2021 on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F3 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.